Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis

被引:3
|
作者
Veettil, Sajesh K. [1 ,2 ]
Kew, Siang Tong [3 ]
Lim, Kean Ghee [4 ]
Phisalprapa, Pochamana [5 ]
Kumar, Suresh [2 ]
Lee, Yeong Yeh [6 ,7 ]
Chaiyakunapruk, Nathorn [1 ,8 ]
机构
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, 30 2000 E, Salt Lake City, UT 84112 USA
[2] Int Med Univ, Sch Pharm, Dept Pharm Practice, Kuala Lumpur 57000, Malaysia
[3] Int Med Univ, Dept Internal Med, Sch Med, Kuala Lumpur 57000, Malaysia
[4] Int Med Univ, Dept Surg, Jalan Rasah, Seremban 70300, Negeri Sembilan, Malaysia
[5] Mahidol Univ, Fac Med, Dept Med, Div Ambulatory Med,Siriraj Hosp, Bangkok 10700, Thailand
[6] Univ Sains Malaysia, Sch Med Sci, Kota Baharu, Kelantan, Malaysia
[7] Natl Univ Malaysia, Fac Med, Gut Res Grp, Kuala Lumpur, Malaysia
[8] Monash Univ Malaysia, Sch Pharm, Subang Jaya 47500, Selangor, Malaysia
关键词
Colorectal cancer; Colorectal adenomas; Chemoprevention; Aspirin; Surveillance colonoscopy; Network meta-analysis; Cost-effectiveness analysis; TRIAL SEQUENTIAL-ANALYSIS; TASK-FORCE; CELECOXIB; CALCIUM; RISK; CHEMOPREVENTION; INTERVENTIONS; RECURRENCE; MORTALITY; REVIEWS;
D O I
10.1186/s12876-021-01715-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundIndividuals with advanced colorectal adenomas (ACAs) are at high risk for colorectal cancer (CRC), and it is unclear which chemopreventive agent (CPA) is safe and cost-effective for secondary prevention. We aimed to determine, firstly, the most suitable CPA using network meta-analysis (NMA) and secondly, cost-effectiveness of CPA with or without surveillance colonoscopy (SC).MethodsSystematic review and NMA of randomised controlled trials were performed, and the most suitable CPA was chosen based on efficacy and the most favourable risk-benefit profile. The economic benefits of CPA alone, 3 yearly SC alone, and a combination of CPA and SC were determined using the cost-effectiveness analysis (CEA) in the Malaysian health-care perspective. Outcomes were reported as incremental cost-effectiveness ratios (ICERs) in 2018 US Dollars ($) per quality-adjusted life-year (QALY), and life-years (LYs) gained.ResultsAccording to NMA, the risk-benefit profile favours the use of aspirin at very-low-dose (ASAVLD,<= 100 mg/day) for secondary prevention in individuals with previous ACAs. Celecoxib is the most effective CPA but the cardiovascular adverse events are of concern. According to CEA, the combination strategy (ASAVLD with 3-yearly SC) was cost-saving and dominates its competitors as the best buy option. The probability of being cost-effective for ASAVLD alone, 3-yearly SC alone, and combination strategy were 22%, 26%, and 53%, respectively. Extending the SC interval to five years in combination strategy was more cost-effective when compared to 3-yearly SC alone (ICER of $484/LY gain and $1875/QALY). However, extending to ten years in combination strategy was not cost-effective.ConclusionASAVLD combined with 3-yearly SC in individuals with ACAs may be a cost-effective strategy for CRC prevention. An extension of SC intervals to five years can be considered in resource-limited countries.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
    Sterne, Jonathan A. C.
    Bodalia, Pritesh N.
    Bryden, Peter A.
    Davies, Philippa A.
    Lopez-Lopez, Jose A.
    Okoli, George N.
    Thom, Howard H. Z.
    Caldwell, Deborah M.
    Dias, Sofia
    Eaton, Diane
    Higgins, Julian P. T.
    Hollingworth, Will
    Salisbury, Chris
    Savovic, Jelena
    Sofat, Reecha
    Stephens-Boal, Annya
    Welton, Nicky J.
    Hingorani, Aroon D.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (09) : 1 - +
  • [22] First-line treatments for advanced hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis in China and the United States
    Sun, Ke-Xin
    Cao, Shan-Shan
    Shi, Feng-Hao
    Guan, Yue
    Tang, Meng
    Zhao, Mei-na
    Jian, Yu-Fan
    Cui, Bin
    Li, Zhi-Yan
    Wang, Jing-Wen
    Yu, Feng
    Ding, Yi
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [23] Risk of Advanced Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality in People With Low-Risk Adenomas at Baseline Colonoscopy: A Systematic Review and Meta-Analysis
    Dube, Catherine
    Yakubu, Mafo
    McCurdy, Bronwen R.
    Lischka, Andrea
    Kone, Anna
    Walker, Meghan J.
    Peirson, Leslea
    Tinmouth, Jill
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (12): : 1790 - 1801
  • [24] A risk-profiling approach for surveillance of inflammatory bowel disease-colorectal carcinoma is more cost-effective: a comparative cost-effectiveness analysis between international guidelines
    Lutgens, Maurice
    van Oijen, Martijn
    Mooiweer, Erik
    van der Valk, Mirthe
    Vleggaar, Frank
    Siersema, Peter
    Oldenburg, Bas
    [J]. GASTROINTESTINAL ENDOSCOPY, 2014, 80 (05) : 842 - 848
  • [25] Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis
    Xu, Weilin
    Qiu, Lei
    Li, Feng
    Fei, Yinjiao
    Wei, Qiran
    Shi, Kexin
    Zhu, Yuchen
    Luo, Jinyan
    Wu, Mengxing
    Yuan, Jinling
    Liu, Huifang
    Mao, Jiahui
    Cao, Yuandong
    Zhou, Shu
    Guan, Xin
    [J]. ORAL ONCOLOGY, 2024, 154
  • [26] Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves
    Obeng-Kusi, Mavis
    Roe, Denise
    Erstad, Brian L.
    Abraham, Ivo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Determining optimal strategies for primary prevention of cardiovascular disease: systematic review, cost-effectiveness review and network meta-analysis protocol
    Uthman, Olalekan A.
    Al-Khudairy, Lena
    Nduka, Chidozie U.
    Court, Rachel
    Mistry, Hema
    Melendez-Torres, G. . J.
    Taylor-Phillips, Sian
    Clarke, Aileen
    [J]. SYSTEMATIC REVIEWS, 2020, 9 (01)
  • [28] Determining optimal strategies for primary prevention of cardiovascular disease: systematic review, cost-effectiveness review and network meta-analysis protocol
    Olalekan A. Uthman
    Lena Al-Khudairy
    Chidozie U. Nduka
    Rachel Court
    Hema Mistry
    G . J. Melendez-Torres
    Sian Taylor-Phillips
    Aileen Clarke
    [J]. Systematic Reviews, 9
  • [29] Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis
    Lin, Liang
    Zhao, Ying J.
    Zhou, Hui J.
    Khoo, Ai L.
    Teng, Monica
    Soh, Lay B.
    Lim, Boon P.
    Sim, Kang
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (02) : 84 - 92
  • [30] Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis
    Yang, Xiuli
    Zheng, Xiaochun
    Hu, Sang
    Huang, Jinlong
    Zhang, Miaomiao
    Huang, Ping
    Wang, Jiangfeng
    [J]. BMC CANCER, 2024, 24 (01)